Neumora officer granted 750,000 stock options

Neumora Therapeutics, Inc. officer Jason Duncan received a grant of stock options covering 750,000 shares of common stock on January 8, 2026.

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. officer Jason Duncan received a grant of stock options covering 750,000 shares of common stock on January 8, 2026. These options give him the right to buy those shares at an exercise price of $2.33 per share. The grant was reported as a direct beneficial ownership position, with 750,000 derivative securities held after the transaction.

According to the vesting terms, 25% of the option shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years. This structure means the option becomes fully vested and exercisable on the fourth anniversary of the vesting commencement date, aligning the officer’s potential equity ownership with longer-term service to the company.

Insider Trade Summary

Grant/Award: 750,000 shares

Grant/Award 1 txn

Insider Duncan Jason

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	750,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 750,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Neumora Therapeutics (NMRA) report for Jason Duncan?

Neumora Therapeutics, Inc. reported that officer Jason Duncan received a grant of stock options for 750,000 shares of common stock on January 8, 2026.

What is the exercise price of Jason Duncan’s Neumora stock options?

The stock option grant to Jason Duncan has an exercise price of $2.33 per share for the underlying Neumora common stock.

How do Jason Duncan’s Neumora stock options vest?

The options vest as follows: 25% of the shares vest on the first anniversary of January 8, 2026, and 1/48th of the total shares vest monthly thereafter so that 100% are vested on the fourth anniversary.

How many Neumora stock options does Jason Duncan hold after this grant?

After the reported grant, Jason Duncan beneficially owns 750,000 derivative securities in the form of stock options related to Neumora common stock.

What is Jason Duncan’s role at Neumora Therapeutics?

The report identifies Jason Duncan as an officer of Neumora Therapeutics, Inc., with the title Chief Legal and Administrative Officer noted in the remarks.

Is Jason Duncan’s Neumora stock option grant reported as directly owned?

Yes. The stock option position for 750,000 derivative securities is reported with an ownership form of Direct (D), indicating direct beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 04:18 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duncan Jason

(Last) (First) (Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL WAY, SUITE 1

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.33	01/08/2026		A		750,000		(1)	01/08/2036	Common Stock	750,000	$0	750,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Title: Chief Legal and Administrative Officer

	/s/ Michael Milligan, as Attorney-in-Fact for Jason Duncan	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.